Table 4. Sensitivity Analyses.

Last Period Outcomes		Main Analysis		V1		V2		V3		V4		V5		V6		V7		V8
				Φ(S2b) from 0.7 to 0.5		Ψ(S2b) from 0.3 to 0.1		u (S2b) from 0.1 to 0.15		u (S1 & S2a) from 0.2 to 0.3		Φ (S2a) from 0 to 0.2		v from 0.005 to 0.05		Presence of patients from 0.95 to 0.85		2nd line costs from $600 to $400
		SFR	LS	SFR	LS	SFR	LS	SFR	LS	SFR	LS	SFR	LS	SFR	LS	SFR	LS	SFR	LS
SZ 2037	S1	5.37	27	5.37	27	5.37	27	5.37	27	5.16	24	5.37	27	5.37	27	4.52	27	6.54	27
	S2a	5.16	187	5.16	187	5.16	187	5.16	187	4.90	148	5.92	196	5.16	187	4.25	187	5.98	187
	S2b	5.88	238	5.02	233	5.56	236	5.53	221	5.88	238	5.88	238	6.38	250	5.30	238	7.04	238
CM 2034	S1	2.27	52	2.27	52	2.27	52	2.27	52	2.15	45	2.27	52	2.27	52	1.87	52	2.82	52
	S2a	2.07	441	2.07	441	2.07	441	2.07	441	2.02	361	2.37	468	2.07	441	1.71	441	2.42	446
	S2b	2.35	598	2.10	584	2.18	591	2.21	490	2.35	598	2.35	598	2.51	609	2.10	598	2.87	598
TZ 2034	S1	0.64	155	0.64	155	0.64	155	0.64	155	0.60	134	0.64	155	0.64	155	0.52	155	0.76	155
	S2a	0.63	1010	0.63	1010	0.63	1010	0.63	1010	0.60	800	0.70	1041	0.63	1010	0.52	1010	0.72	1010
	S2b	0.69	1334	0.62	1318	0.63	1315	0.65	1243	0.69	1334	0.69	1334	0.73	1388	0.61	1334	0.82	1334